ENATRANS project launch - Enabling nanomedicine solutions for healthcare by supporting translation from lab to bedside
This European project aims at supporting nanomedicine solutions notably by enhancing translation along the R&D process, at increasing chances of commercial uptake for promising technologies, and to a large extent, at supporting SMEs as essential players in the transformation of cutting edge technologies into innovative medical products. Funded by the European Commission for a 3-year period, ENATRANS is covered by a 2 M€ allocation. Patrick Boisseau, Head of Business Development Nanomedicine at CEA-Leti and chairman of the ETPN, comments: “ENATRANS provides a small-scale platform for the Translation of Nanomedicine with the aim to proof the Translation Hub concept as described in the ETPN White Paper published in 2013. Partners in the ENATRANS project drive the emergence of a dynamic pan-European network of industrial, SMEs, academic, clinical, investors and public stakeholders and establish functional interfaces between all these actors. ENATRANS is of outmost importance for the nanomedicine community as it will build a functioning supply chain of innovative projects, mainly ran by SMEs and ready to meet industrial, commercial and clinical needs.” The main objectives of the project are to: - Enhance innovation skills and capacities of SMEs and academia in their translation endeavours, - Improve knowledge about regulation, standardisation, reimbursement and business aspects of the research community and especially SMEs, - Establish functional interfaces between R&D actors, clinical trial centres, investors and large companies. ENATRANS is therefore providing stakeholders in the nanomedicine sector with a set of services, tools and infrastructures complying with the needs and time constrains of SMEs. As a cornerstone instrument, the Nanomedicine Translational Advisory Board (TAB), consisting of high-level senior translation experts and education tools designed to the needs and time constrains of SMEs, will provide specific advice, guidance and recommendations to all nanomedicine actors in need of assistance and dealing with translation issues to drive their projects in the right direction i.e. to reach the market. Two further instruments will be proposed to the community, to serve best the nanomedicine community and to increase awareness of the healthcare sector: - The ENATRANS SME² (SME square): a physical and virtual networking platform which will promote exchanges and learning from others’ individual experiences. The SME² will be a gateway to identify specific needs of SMEs, for instance in training, but also opportunities, barriers, success factors or best/bad practices and to help them solving these in a collaborative way. Further community building tools will also serve the whole spectrum of actors. - Showcases: new editions of the Nanomed Awards are planned with the aim to showcase excellent nanomedicine technologies towards large industries and investors, as well as new editions of the Nano World Days, a series of simultaneous events across Europe targeting essentially media, scientific communities and public to explain nanomedicine uses in specific areas of healthcare (oncology, cardiology, neurology…) and to increase their awareness on the benefits offered by such solutions. ENATRANS involves seven partners across Europe with a long track record in supporting effective translation of nanobiomedicine: VDI/VDE-IT (Germany) hosting the ETPN Secretariat, CEA-Leti (France), Bioanalytik-Muenster e.V. (Germany), Nanobiotix SA (France), Fondazione Don Carlo Gnocchi ONLUS (Italy), Tel-Aviv University (Israel) and TecMinho (Portugal). ENATRANS started officially on 1st January 2015.
Schlüsselbegriffe
Länder
Germany, France, Israel, Italy, Portugal